CA2123228A1 - Conjugues de sous-unites du cmh utiles dans l'amelioration des deficiences immunitaires - Google Patents

Conjugues de sous-unites du cmh utiles dans l'amelioration des deficiences immunitaires

Info

Publication number
CA2123228A1
CA2123228A1 CA002123228A CA2123228A CA2123228A1 CA 2123228 A1 CA2123228 A1 CA 2123228A1 CA 002123228 A CA002123228 A CA 002123228A CA 2123228 A CA2123228 A CA 2123228A CA 2123228 A1 CA2123228 A1 CA 2123228A1
Authority
CA
Canada
Prior art keywords
peptide
mhc
complex
antigen binding
binding site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002123228A
Other languages
English (en)
Inventor
Bishwajit Nag
Brian R. Clark
Somesh D. Sharma
Harden M. Mcconnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2123228A1 publication Critical patent/CA2123228A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002123228A 1991-11-19 1992-11-18 Conjugues de sous-unites du cmh utiles dans l'amelioration des deficiences immunitaires Abandoned CA2123228A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79393891A 1991-11-19 1991-11-19
US07/793,938 1991-11-19

Publications (1)

Publication Number Publication Date
CA2123228A1 true CA2123228A1 (fr) 1993-05-27

Family

ID=25161218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002123228A Abandoned CA2123228A1 (fr) 1991-11-19 1992-11-18 Conjugues de sous-unites du cmh utiles dans l'amelioration des deficiences immunitaires

Country Status (5)

Country Link
EP (1) EP0661996A4 (fr)
JP (1) JPH07501526A (fr)
AU (1) AU3220693A (fr)
CA (1) CA2123228A1 (fr)
WO (1) WO1993009810A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232875T2 (de) * 1991-04-23 2003-08-21 Anergen, Inc. MHC-Konjugate zur Verbesserung der Autoimmunität.
WO1993012145A1 (fr) * 1991-12-19 1993-06-24 Baylor College Of Medicine Conjugues d'alcool polyvinylique ou de polyethyleneglycol de peptides utilises dans l'immunodepression specifique d'epitotes
EP1138766A3 (fr) * 1992-10-15 2003-05-02 Toray Industries, Inc. Procédé pour produire une proteine d'antigenes majeurs d'hystocompatibilité classe II et materiaux sur lequels elle est immobilisée
US6045796A (en) * 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
WO1995027505A1 (fr) * 1994-04-12 1995-10-19 Biomira, Inc. Antigenes specifiques d'une reponse immunitaire cellulaire et leurs utilisations
JPH10503379A (ja) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド Ｍｈｃ複合体およびその用途
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
BR9509438A (pt) * 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
WO1997008328A1 (fr) * 1995-08-30 1997-03-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Elimination selective des lymphocites t reconnaissant des cibles specifiques preselectionnees
EP0869176A4 (fr) * 1995-11-07 2000-09-20 Kaneka Corp Autoantigenes
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
JP7270946B2 (ja) * 2017-08-08 2023-05-11 国立大学法人浜松医科大学 自己免疫疾患の治療又は予防剤
JPWO2019054409A1 (ja) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Ｈｌａタンパク質に相互作用する物質のスクリーニング方法及びスクリーニング用キット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
CA2056450A1 (fr) * 1989-05-31 1990-12-01 Dennis A. Carson Mode de traitement de la polyarthrite rhumatoide
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
AU3220693A (en) 1993-06-15
EP0661996A4 (fr) 1997-05-21
WO1993009810A1 (fr) 1993-05-27
EP0661996A1 (fr) 1995-07-12
JPH07501526A (ja) 1995-02-16

Similar Documents

Publication Publication Date Title
US5284935A (en) MHC-mediated toxic conjugates useful in ameliorating autoimmunity
US5260422A (en) MHC conjugates useful in ameliorating autoimmunity
US5734023A (en) MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US6451314B1 (en) MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5130297A (en) Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US6815171B2 (en) Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
CA2123228A1 (fr) Conjugues de sous-unites du cmh utiles dans l'amelioration des deficiences immunitaires
US6007820A (en) Purification and characterization of MHC-peptide complexes useful in ameliorating autoimmunity
JP5118969B2 (ja) Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
US5824315A (en) Binding affinity of antigenic peptides for MHC molecules
US20050003431A1 (en) Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
AU673985B2 (en) CD8 binding domain peptides
EP0630255B1 (fr) Conjugues cmh permettant de traiter l'auto-immunite
WO1995011702A1 (fr) Expression procaryote de proteines du cmh
Fukushima et al. Permissive recognition of immunodominant determinants of the retinal S-antigen in different rat strains, primates and humans.
CZ20023586A3 (cs) Přípravky obsahující izolované potenciálně imunodominantní peptidy z podjednotky alfa acetylcholinového receptoru

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead